22 February 2022

Dear members of SMA Europe,

Today we are pleased to announce that worldwide recruitment has completed for the RAINBOWFISH clinical trial, which investigates the efficacy and safety of risdiplam in infants with pre-symptomatic SMA[1]. This milestone marks the enrolment of 26 participants from across the globe. As part of our ongoing partnership and following your request to receive important and timely updates about Roche's SMA clinical programme, we wanted to share this news and update you on what happens next.

This achievement is a result of the SMA community's commitment, and we are very grateful to all trial participants, their families, the clinical trial sites and staff, and the broader SMA community who have supported the design, initiation and recruitment phases of the study and our entire clinical development programme.

What happens now that recruitment is complete?

Whilst recruitment completion is exciting news, the diligent work of trial participants and researchers is ongoing. All participants will receive risdiplam for 2 years as part of the RAINBOWFISH study. Afterward they may enter an open label extension phase that would continue for at least 3 additional years.

When will RAINBOWFISH study results be available?

Overall primary results of the study are expected in early 2023, after all participants have had the opportunity to complete 12 months of treatment from when they enrolled. However, interim (preliminary) data from the RAINBOWFISH study are already available and have been submitted to the European Medicines Agency (EMA) as part of an application to extend risdiplam's currently approved indication in Europe for patients younger than 2 months old. This application was accepted by the EMA on 17 January, which means that EMA's Committee for Medicinal Products for Human Use (CHMP) will now conduct a formal scientific evaluation. A positive decision by the CHMP would expand the approved use of risdiplam to infants with SMA across all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

Are there other risdiplam clinical studies planned?

MANATEE is now the only Roche-sponsored global clinical trial commencing recruitment in early 2022. MANATEE is a two-part, global Phase 2/3 clinical study, which aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in ambulant (able to walk independently) children with SMA aged 2-10 years[2]. More information about MANATEE and its trial sites can be found on the ClinicalTrials.gov website (Identifier: NCT05115110).

More information on SMA clinical trials conducted around the world can be accessed on ClinicalTrials.gov.

We want to thank the community again for its support and interest in the risdiplam clinical development programme.

If you have any questions about this update, please do not hesitate to contact us.

Sincerely,

Fani Petridis

Fani Petridis, on behalf of the Roche Global SMA Team
Senior Global Patient Partnership Director, Rare Diseases (SMA)

M-XX-00008051

[1] https://clinicaltrials.gov/ct2/show/NCT03779334?term=Rainbowfish&draw=2&rank=1

[2] https://clinicaltrials.gov/ct2/show/NCT05115110?term=risdiplam&draw=2&rank=3